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Background: Smoking remains the most common preventable cause of death. Very little 
tobacco exposure can increase cardiovascular disease risk. The relationship between smoking, 
sex, and weight remains unclear.
Methods: Between September 1992 and June 2007, 2582 consenting patients starting the 
Ottawa Hospital Weight Management program were grouped by sex and smoking status. “  Former 
  smokers” (771 females, 312 males) had quit for at least 1 year. “Smokers” (135 females, 54 males) 
smoked .9 cigarettes daily. There were 979 females and 331 males who never smoked. Using 
SAS 9.2 statistical software, the prevalence of coronary artery disease (CAD), type 2 diabetes 
(T2DM), major depressive disorder (MDD), and medication use among the groups was com-
pared (Chi-square [χ2]). Anthropometric measurements, lipid, glucose and thyroid levels were 
compared using analysis of variance (ANOVA). Interactions were assessed using 2-way ANOVA 
analysis for continuous data, and logistic regression for discrete data.
Results: Smokers were more likely to have MDD (χ2), lower high-density lipoprotein levels and 
higher triglyceride levels than other groups. Former smokers had a greater prevalence of CAD, 
T2DM on pharmacotherapy, and impaired fasting glucose than other groups. They were also 
more likely to be taking lipid-lowering agents and antihypertensives (χ2). Never smokers had 
less MDD, CAD, and were less likely to be on antidepressants than the other groups. Males were 
more likely to have CAD and T2DM than females. Females were more likely to have MDD than 
males. Interactions between smoking status and sex were found for age, weight, fasting glucose 
and thyroid-stimulating hormone levels.
Conclusion: Obese never smokers suffer from the fewest chronic diseases. Obese former smok-
ers have a greater prevalence of CAD, T2DM on pharmacotherapy, and impaired fasting glucose 
than other groups. Thus, clinicians and researchers should avoid combining former smokers with 
never smokers as “nonsmokers” in research and treatment decisions. The results of this study 
call for a longitudinal study comparing these groups over the weight management program.
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Introduction
Obesity has reached epidemic proportions worldwide with associated health care costs 
exceeding $100 billion annually.1 Obesity-associated medical conditions include: type 2 
diabetes (T2DM), atherosclerosis, and obstructive sleep apnea.2 Obesity is second 
only to cigarette smoking as the leading preventable cause of death and illness.1 Many 
  studies have documented a U- or J-shaped curve for mortality as it relates to body mass 
index (BMI), with individuals with both low and high BMIs experiencing an increased 
mortality rate.3 Koster et al showed that an especially high mortality risk results when 
obesity or a large waist circumference is combined with smoking. The investigators 
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found that mortality rates increased as BMI increased, and 
that the rates increased from never smoker to former smoker 
to current smoker. In addition, obesity combined with cur-
rent smoking increases circulatory disease mortality by 6- to 
11-fold for people under the age of 65 years.4 Weight control 
measures may be more prevalent in women than men,5 and 
in a study of body image, men were more likely to be satis-
fied with their weight than women.6 Smoking has been more 
commonly viewed as a weight control method for women 
than for men, and used for that purpose.7 In a related study of 
surgical intervention for weight loss, men were more likely 
to be motivated by medical problems than women.8
The Ottawa Hospital–Civic Campus Weight Management 
clinic provides a unique multidisciplinary weight manage-
ment program for obese and overweight individuals consist-
ing of a year-long course in lifestyle modification, and total 
meal replacement typically for the first 12 weeks.9,10
In 2001, we published9 a study of 968 consecutive 
patients in this program that examined whether smokers and 
nonsmokers starting a weight loss program differ in their 
cardiovascular risk factors. While the smokers had larger 
waist sizes, higher blood pressures and lower high-density 
lipoprotein (HDL) levels, both groups derived clear benefit 
from a 900 kcal meal replacement weight management 
  program. In that study we combined former smokers and 
never smokers as “nonsmokers”. What is unknown is whether 
the male and female former smokers in the Ottawa Weight 
Management Clinic population represent a unique population 
of their own, with unique baseline characteristics at weight 
management initiation, and as such should be separated from 
the male and female never smokers as we investigate our 
program’s effects in the future.
Here we examine the baseline characteristics of a larger 
number of male and female smokers, former smokers and 
never smokers starting the same multidisciplinary weight 
management program with a view to perhaps one day tailor-
ing the program to their specific needs. Unlike our previous 
study,9 this one investigates a much broader range of physio-
logical and behavioral variables with plans to look at program 
effects on all of them in future studies. A better understanding 
of the relationship between smoking history and sex and the 
motivation to begin weight management treatment would 
help physicians to better counsel and tailor weight manage-
ment programs to specific patient subgroups.
The objectives of the present study include: (1) To inves-
tigate the relationship between obese patients’ smoking status 
and their baseline characteristics at the initiation of weight 
management; (2) To investigate the relationship between 
obese patients’ sex and their baseline characteristics at the 
initiation of weight management; and (3) To investigate 
the interaction of obese patients’ sex and smoking status as 
they relate to their baseline characteristics at the initiation 
of weight management.
Methods
Criteria for referral to The Ottawa 
Hospital Weight Management Clinic
The source population includes: citizens of Ottawa and the 
surrounding communities in the province of Ontario, Canada. 
Physicians typically refer patients to the weight management 
program if they have a BMI of 30 and over, or a BMI of 25 and 
above with associated T2DM, hypertension, or CAD. These 
patients have been included in this study.
Procedures
Patients enter The Ottawa Hospital Weight Management 
Clinic protocol in closed groups of 23, meet for weekly 
interactive teaching sessions for 26 weeks and then 
monthly for 6 months using Optifast® Behavioral Modules 
(Nestle Health Science, Vevey, Switzerland). For the first 
12 weeks patients are typically on Optifast 900 kilocalorie 
meal replacement. Data on initial history, physical exam, 
and laboratory testing protocol are entered in the Ottawa 
Weight Management Clinic database.9,10 Data for this study 
were extracted from this database, and it includes all of the 
available information on 2582 patients from September 
1992 to June 2007.
At their first visit, patients referred to the Ottawa Weight 
Management program are asked to fill out a detailed ques-
tionnaire concerning smoking status, alcohol use, previous 
diagnosis of depression by a physician, previous weight-loss 
attempts, current medications and general health. Please refer 
to Table 1 for questions relating to smoking behaviours.9,10 
Patients are weighed, their waist circumference is measured, 
their BMI is calculated, and their resting blood pressure is 
recorded. Blood is drawn to assess the patient’s lipid pro-
file which includes: HDL, low-density lipoprotein (LDL), 
  triglycerides (TG), apolipoprotein-B (apo-B), thyroxin levels, 
thyroid-stimulating hormone (TSH) levels, triiodothyronine 
(T3), glucose levels, insulin levels, and hemoglobin-A1c 
(Hba-1C). A diagnosis of coronary artery disease (CAD) is 
based on a documented cardiac event or imaging to prove 
a cardiac event. A diagnosis of major depressive disorder 
(MDD), impaired fasting glucose (IFG), type 2 diabetes 
(T2DM), and hypertension is based on the patient’s self-
reported past medical history.
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To better define the groups, and in accordance with 
Persky et al,11 smokers of 10 or more cigarettes per day 
were used for the present study. Smokers of less than 10 
cigarettes per day were not included in the analysis because 
of the wide variation in cigarette number and the inconsis-
tency of smoking behavior reported in this group. Given 
that physiologic differences have been found based on 
the quantity of cigarettes smoked,12 heavy smokers (10 or 
more cigarettes) were separated from the lighter smokers 
for the purposes of statistical and clinical accuracy. The 
present study focused on heavy smokers who are at greater 
health risk than light smokers. Thus, the term “smoker” 
is defined as an individual smoking at least 10 cigarettes 
per day or more.
Former smokers were divided into those   individuals 
who quit less than 1 year ago, and those who quit 1 year 
Table  1  A  Sample  of  the  weight  management  clinic  intake 
questionnaire
A. Which statement best describes your smoking history?
  I have never smoked.
  I smoke. (If so, how many cigarettes per day?)
  I quit smoking. (If so, how many years ago?)
B.   How many times during your life have you stopped smoking for more 
than 4 weeks?
C. For how many years have you smoked?
D.   On average, how many cigarettes per day have you smoked over this 
time?
Other topics include:
  Have you ever been diagnosed with high blood pressure?
    Have you ever been diagnosed with obstructive sleep apnea? Have 
you ever used a CPAP machine? etc
Note: For full detail on the clinic questionnaire, refer to Dent et al.10
ago or more as per the literature.5 Only the former smokers 
of 1 year or more were used. According to the literature,13 
transient weight changes are expected within the first 
12 months of smoking cessation, and we chose a minimum 
of 1 year smoking cessation for a baseline weight measure-
ment as result. Therefore, for the purpose of this study, 
“former smokers” refers to those individuals who have 
quit smoking for 1 year or more at the time of program 
initiation. Please refer to Figure 1 for further details on the 
population breakdown. The two groups that are found in 
boxes labeled with an X above them were excluded from 
the analysis. Table 2 represents a description of the study 
population.
With the aim of removing confounding variables when 
looking for statistical significance, blood pressure data 
is reported for patients who are not on antihypertensive 
medications. Similarly, lipid data including: HDL, LDL 
and TG levels are reported for patients who are not on lipid-
lowering agents. Glucose and Hba1c data is reported for 
patients not being treated for T2DM either with medication 
or insulin. TSH and T3 data is reported for patients not on 
T3 supplementation.
Ethics
Ethics approval was obtained by way of formal application 
to the Ottawa Hospital Research Ethics Boards. Patients 
consented to their data being included for the purpose of 
this research. Written informed consent was obtained from 
all participants. Every patient whose data is provided in this 
study agreed to his/her data being published. In addition, we 
have no conflicts of interest to declare.
x x
Total patient population
N = 2860
Former smokers
N = 1191
Smokers
N = 359
Smokers
<10 cigarettes
per day
N = 170
Smokers
10 or greater
cigarettes
per day
N = 189
Smoking cessation
less than 1 year ago
N = 108 
Smoking cessation
1 year ago or longer
N = 1083 
Males
54
Males
44
Females
126
Females
135
Males
32
Males
312
Females
76
Females
771
Males
331
Females
979
Never smokers
N = 1310
Figure 1 Division of the patient population based on smoking history and sex.
Notes: Patients were grouped according to their smoking status and then by their sex. Patient groups that have been placed within the two boxes labelled with X’s were 
not included in the analysis for reasons explained in the methods section. X-indicates removed from study analysis.
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Table 2 Comparing male and female smokers, former smokers, and never smokers, across continuous physiological variables at 
program initiation
Smoking Status  Sex
Female 
N = 1885
Male 
N = 697
Smoker 
N = 135
Former smoker 
N = 771
Never smoker 
N = 979
Smoker 
N = 54
Former smoker 
N = 312
Never smoker 
N = 331
Age* (SD)  51.8 (10.7) 
135
57.1 (10.7) 
771
52.3 (12.0) 
979
50.7 (11.4) 
54
60.2 (9.7) 
312
51.8 (11.2) 
331
BMI (SD)  463 (6.7) 
123
45.0 (6.0) 
701
44.2 (6.0) 
899
55.1 (7.6) 
49
53.3 (6.4) 
270
53.8 (7.1) 
307
Weight* (1bs) (SD)  249.8 (51.4) 
135
245.9 (49.3) 
771
242.6 (46.9) 
979
323.5 (69.1) 
54
302.4 (62.5) 
312
309.7 (70.1) 
331
WC (inches) (SD) 42.0 (7.8)
135
41.7 (8.2)
769
41.1 (7.6)
976
45.8 (9.5)
54
43.8 (8.9)
312
44.9 (9.6)
331
Systolic BP (mmHg) (SD) 128.9 (20.6)
75
130.6 (14.8)
366
129.7 (13.9)
501
134.8 (11.7)
31
136.7 (11.1)
130
135.7 (29.3)
183
Diastolic BP (mmHg) (SD) 80.6 (11.5)
75
81.7 (8.9)
366
81.5 (7.6)
501
82.8 (12.0)
31
84.4 (11.1)
130
84.9 (7.8)
183
Glucose* (mmol/L) (SD) 5.5 (1.4)
105
5.5 (1.2)
589
5.3 (1.1)
790
5.5 (1.3)
39
6.0 (1.7)
218
5.5 (1.3)
256
TSH* (mU/L) (SD) 2.2 (1.5)
95
2.6 (3.4)
535
2.4 (1.7)
731
2.0 (1.6)
43
2.2 (1.7)
261
2.3 (1.3)
272
Notes: Mean values are presented ± standard deviation (SD). Waist circumference (WC) in inches, blood pressure (BP) measured in mmHg, thyroid-stimulating hormone 
(TSH) (mU/L), fasting blood glucose (Glucose) (mmol/L). BP reported for patients who are not on medications which alter it. TSH values are presented for patients not on 
thyroid-hormone replacement. Glucose data is presented for patients not being treated for T2DM. *Interactions were found for smoking status and sex with respect to 
age of program initiation, baseline weight, fasting blood glucose and TSH in patients not on T3/T4 supplementation (P , 0.05). All values in italics represent the number of 
patients for which a result was available.
Abbreviation: BMI, body mass index; T2DM, type 2 diabetes mellitus.
Statistical analysis
Using SAS software (v 9.2; SAS Institute, Cary, NC), 
statistical analysis was performed on the data, namely one-
way ANOVA analysis, followed by Tukey’s HSD post-hoc 
analysis for the continuous data. Chi-square analysis was 
employed for the discrete data, using Fisher’s exact test in 
the instance of an expected value below 5.14 For continuous 
data, 2 × 2 interactions were studied using two-way ANOVA 
for items such as: age, waist circumference, and TSH data 
for which a P-value ,0.05 was accepted as statistically sig-
nificant. Logistic regression was used for the discrete data 
which include: a diagnosis of CAD, or MDD, for which a 
P-value ,0.05 was accepted as statistically significant.
Results
The flow diagram for this population is given in Figure 1. 
Never smokers was the most common grouping, followed by 
former smokers, and then smokers. Each category appeared 
representative of the overall 2.7:1 female:male ratio of the entire 
population. The ratio of smokers of less than 10   cigarettes per day 
to smokers of 10 cigarettes a day or more was approximately 1:1, 
while the population of former smokers was approximately 90% 
quitters of 1 year or more. The mean number of years quit for 
males was 15.0 years, and for females 13.2 years.
A description of the baseline variables from our study 
group of 2582 patients based on sex and smoking status is 
presented in Table 2. A 2 × 2 ANOVA analysis of age, weight, 
fasting blood glucose and TSH with sex and smoking revealed 
interactions (P , 0.05). With respect to age, the mean age 
for the population was 54.6 ± 11.5 years. Male and female 
smokers were the youngest in the group, whereas male and 
female former smokers were the eldest. The mean weight 
for the male population was 307 ± 66.9 pounds, while the 
mean weight for the female population was 244.4 ± 48.3 
pounds. Male and female smokers were the heaviest for 
their particular sex (male mean 323.5 ± 69.1 pounds, female 
mean 249.8 ± 51.4 pounds), whereas never smokers were 
the lightest females (242.6 ± 46.9 pounds), and former 
smokers were the lightest males (302.5 ± 62.5 pounds).   
The glucose data was restricted to patients not being treated 
for T2DM, and male former smokers had the highest fast-
ing blood glucose (6.0 ± 1.7 mmol/L), yet the mean was 
within the normal range. Extreme fasting glucose levels 
for “nondiabetic” male former smokers crossed the normal 
range. Male smokers appeared to have the lowest TSH   levels 
(2.0 ± 1.6 mU/L), while female smokers had the highest 
TSH levels (2.2 ± 1.5 mU/L). The mean blood pressure for 
the entire population is 135.4 mmHg (±17.2)/83.2 mmHg 
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(±8.5), however this is for the patients who were not on blood 
pressure altering medications.
Smokers had the largest waist circumferences (males 
mean 45.8 ± 9.5 inches, females mean 42.0 ± 7.8 inches) 
and they had the highest triglyceride levels after removal of 
patients on lipid lowering drugs (mean 2.0 ± 1.0) (Table 3). 
Former smokers had significantly higher total cholesterol 
(5.4 ± 1.0 mmol/L), and HDL levels (1.2 ± 0.2 mmol/L) 
than smokers. Former smokers had higher LDL levels 
(3.4 ± 0.8 mmol/L) than never smokers. Smokers had higher 
TG levels (2.0 ± 1.0 mmol/L) than former   smokers and never 
smokers.
Former smokers in the treatment-seeking population had 
an increased prevalence of impaired fasting glucose, were 
more likely to have medically treated type 2 diabetes, and 
to be on antihypertensive medication than the other groups 
as shown by Chi-square test (Table 4A). Never smokers 
were less likely to use alcohol in excess of the suggested 
amounts, and were less likely to be on lipid-lowering agents 
and antidepressants than the other groups as shown by Chi-
square test.
Men in the treatment-seeking population had an increased 
prevalence of T2DM (treated and untreated, Table 4B) 
compared to women. Men were more likely to be taking 
lipid-lowering medications, antihypertensives, exceeding 
the suggested weekly alcohol intake, and to have a diag-
nosis of CAD than women. Women were more likely to be 
diagnosed with depression, to be taking antidepressants, 
and to be on T3 or T4 supplements than men, as shown by 
Chi-square test.
After Chi-square analysis of the data in Table 4A and 
B was performed, logistic regression was performed to 
investigate any significant 2 × 2 interactions of smok-
ing status with sex for each of the discrete variables 
presented. All P-values obtained from this analysis were 
greater than 0.05, and as such no 2 × 2 interactions were 
noted.
Males had greater waist circumferences (53.7 ± 6.9 inches 
versus 44.7 ± 6.1 inches) and higher blood pressure values for 
both systolic (135.6 ± 24.3 mmHg versus 129.8 ± 15.4 mmHg), 
and diastolic (84.5 ± 9.6 mmHg   versus 81.5 ± 8.5 mmHg), 
had worse lipid profiles, and were at a higher risk for T2DM 
than females (Table 5). Obese females were more likely to 
suffer from decreased T3 production than males. Known 
sex differences such as females with higher HDL levels 
than men (1.3 ± 0.3 mmol/L versus 1.0 ± 0.2 mmol/L), 
and men with higher TG levels (2.04 ± 1.1 mmol/L versus 
1.7 ± 0.9 mmol/L) were also evident.15
Table 3 Comparing smokers (S), former (FS), and never smokers (nS) across continuous physiological variables at program initiation
Smoking status Smoker 
N = 189
Former smoker 
N = 1083
Never smoker 
N = 1310
Description
WC (inches) (mmHg) (SD)* 48.8 (8.0) 47.3 (7.2) 46.6 (7.57) S . FS, S . nS
170 971 1206
Systolic BP (mmHg) (SD) 130.6 (18.6) 131.6 (16.6) 131.3 (19.5)
106 497 683
Diastolic BP (mmHg) (SD) 81.2 (11.6) 82.4 (9.6) 82.4 (7.8)
106 497 683
Total chol (SD)* 5.2 (1.0) 5.4 (1.0) 5.20 (0.96) FS . S
132 770 1019
HDL ± (mmol/L) (SD)* 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) FS . S
132 764 1004
TG* ± (mmol/L) (SD) 2.0 (1.0) 1.8 (1.0) 1.7 (0.9) S . FS, S . nS
134 759 1014
LDL* (mmol/L) (SD) 3.3 (0.8) 3.4 (0.8) 3.2 (0.8) FS . nS
126 727 978
ApoB* (g/L) (SD) 1.1 (0.3) 1.1 (0.3) 1.0 (0.2) FS . nS
29 434 648
Hba-1c (SD) 0.06 (0.006) 0.06 (0.08) 0.06 (0.01)
42 270 376
T3 (pmol/L) (SD) 4.1 (0.80) 4.0 (0.7) 4.0 (0.8)
77 558 718
Notes: Mean values are presented ± standard deviation (SD). *Indicates a significant difference at P , 0.05. Waist circumference (WC) in inches, blood pressure (BP) in 
mmHg, high-density lipoprotein (HDL) (mmol/L), triglycerides (TGs) (mmol/L), low-density lipoprotein (LDL) (mmol/L), apo-lipoprotein-B (Apo-B) (g/L), hemoglobin-alc 
(Hba-1c), Triiodothyronine (T3) (pmol/L). The description column explains which groups have a higher value (.) for the particular variable studied. BP data is reported for 
patients who are not on medications which alter it. Lipid data is reported for patients who are not on lipid-lowering agents. Glucose and Hba-1c data is reported for patients 
not being treated for T2DM. T3 data is reported for patients on thyroid-hormone supplementation. All values in italics represent the number of patients for which a result 
was available.
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Discussion
Separating patients entering the Ottawa Weight Manage-
ment Clinic program into groups based on smoking status 
and sex did reveal significant baseline differences.   Smokers 
were more likely to have a diagnosis of MDD, lower HDL 
and higher triglyceride levels than the other groups.   Former 
smokers had a greater prevalence of CAD, T2DM on 
pharmacotherapy, and impaired fasting glucose than smokers 
and never smokers. They were also more likely to be taking 
lipid-lowering agents (LLAs), and to be on antihypertensives 
than the other two groups as well. Former smokers who are 
not taking LLAs had higher HDL levels than smokers. The 
never smokers group had fewer MDD and CAD diagnoses, 
and they were less likely to be on antidepressants than the 
other two groups. Males were more likely to be suffering 
from CAD and T2DM than females. Females were more 
likely to suffer from MDD than males. Interactions between 
smoking status and sex were found for age, weight, fasting 
blood glucose and TSH levels.
The results obtained from our study population do not 
completely agree with the literature, or expectation. In 
a US study, smokers weighed on average 3 kg less than 
nonsmokers, and smoking cessation can result in a weight 
gain of 6 kg on average over a 1-year period.6 This was not 
found to be the case in our study population. However, our 
study population does not represent a random sample, as 
patients were selected based on a unique treatment criteria 
as described in our study methods. Smokers were found to be 
the heaviest group – which may represent patients for whom 
smoking did not serve as a good weight control measure. 
Therefore, the results of this study are meant to be used by 
clinicians whose patients reflect the demographics in our 
study population. In fact, female former smokers were the 
lightest group in the study population. Lerman et al17 sug-
gest that the increase in body weight that occurs following 
smoking cessation is related to increases in food reward 
and food reward is determined at least in part by genetic 
factors.16 However, since we only used former smokers 
who had quit for a minimum of 1 year, the female former 
smokers may represent a group of people who have already 
been consciously monitoring their weight to an extent prior 
to program entry, and have been enrolled in the program for 
additional assistance.
The association between serum lipids increase and BMI 
increase is significant and strong, and is greater for men than 
for women.17 Smokers had elevated triglyceride levels which 
is consistent with the literature,12 however, it must be noted 
that patients requiring lipid management medications were 
removed from the analysis. In addition, the literature suggests 
that smoking leads to increased waist circumference, and 
smokers were found to have the largest waist circumference in 
this population.18 Former smokers have a greater prevalence of 
hypertension, history of cardiovascular disease, alcohol over-
use, and T2DM than never smokers. Furthermore, there is an 
increased prevalence of former smokers with impaired fasting 
glucose which may be related to insulin resistance secondary 
Table  4A  Comparing  smokers,  former  smokers,  and  never 
smokers across discrete variables at program initiation
Variable 
Smoker 
N = 189 (%)
Former  
smoker 
N = 1083 (%)
Never  
smoker 
N = 1310  (%)
IFG* 1.6 5.9 4.4
T2DM not on meds* 6.4 6.1 3.3
T2DM on meds* 5.8 14.0 7.6
On lipid-lowering agents* 13.3 15.4 9.7
On antihypertensives* 20.6 35.1 26.9
Alcohol . suggested* 8.5 8.4 3.1
Dx of CAD* 2.1 8.6 3.2
Dx of depression 11.1 6.9 7.1
On antidepressants* 34.4 29.2 23.9
On T4 supplementation 12.7 15.3 12.5
Notes: Chi-square analysis (χ2) was performed, and P-values of ,0.05 accepted 
at significant (*). Impaired fasting glucose (IFG), diabetes (DM), suggested alcohol 
intake for a male is no more than 14 drinks per week, and no more than 11 for a 
women. Coronary artery disease (CAD) was determined based on the diagnosis of 
a cardiac event or imaging to prove a cardiac event. All data is presented as a % of 
the population exhibiting the particular trait.
Table 4B Comparing males and females across discrete variables 
at program initiation
Variable  
Males 
N = 697 (%)
Females 
N = 1885  (%)
IFG* 6.0 4.4
T2DM not on meds* 6.5 4.0
T2DM on meds* 15.2 8.3
On lipid-lowering agents* 20.3 9.4
On antihypertensives* 41.2 25.7
Alcohol . suggested* 10.1 4.1
Dx of CAD* 12.1 2.9
Dx of depression 5.3 8.1
On antidepressants* 18.7 29.9
On T4 supplementation 5.6 16.7
Notes: Chi-square analysis (χ2) was performed, and P-values of ,0.05 accepted 
at significant (*). Impaired fasting glucose (IFG), diabetes (DM), suggested alcohol 
intake for a male is no more than 14 drinks per week, and no more than 11 for a 
women. Coronary artery disease (CAD) was determined based on the diagnosis of 
a cardiac event or imaging to prove a cardiac event. All data is presented as a % of 
the population exhibiting the particular trait.
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to adipose deposition around the waist from years of heavy 
smoking, or from increased weight gain post-smoking cessa-
tion. According to the Framingham study, the life expectancy 
of obese smokers is 13 years less than normal weight non-
smokers. There is also evidence to support the hypothesis that 
smoking affects body fat distribution associated with central 
obesity and insulin resistance.19
The former smoker group may represent a population 
who are seeking to reform their lives after a shocking medical 
event such as a heart attack, or the diagnosis of T2DM. The 
literature shows that smoking cessation yields substantial 
health benefits.1,17 Never smokers appear to suffer from fewer 
chronic illnesses than both smokers and former smokers. 
Never smokers are also less likely to be on antidepressant 
medication than smokers and former smokers. This may 
be explained by further research in the common dopamine 
pathways of addiction to smoking and addiction to food and 
the relationship of mood with addiction.20
Males in the obesity treatment program are more likely 
to be suffering from chronic illnesses like diabetes and 
coronary artery disease. This may suggest that men require 
adverse health events as motivators for weight management. 
As stated previously, men are also more likely to seek surgery 
for weight loss for medical reasons than women.8 Women 
may be more concerned with body image.6 The increased 
prevalence of depression and antidepressive medication use 
among women may reflect a negative body image, or a pos-
sible explanation for disordered eating patterns.
Interactions between smoking status and sex were found 
for age at program initiation, weight, fasting blood glucose 
and TSH levels. Therefore, physician counseling about weight 
management should be responsive to the sex and smoking 
status combination of each patient. For example, a young 
female former smoker may be seeking to improve her body 
image after weight gain from smoking cessation. An older 
male smoker may require weight management to treat his 
T2DM, which may be the most important therapeutic task 
for this patient group.21
A limitation of this study is the small number of male 
smokers (n = 54) and female smokers (n = 135), espe-
cially those with proper medical management. The data 
on   smoking status was based on self-report questionnaires 
which are subject to numerous forms of responder bias and 
recollection errors. In addition, we did not divide former 
smokers into former light, and former heavy smokers since 
many former smokers had great difficulty remembering if 
they smoked nine cigarettes a day or ten or more. We did 
not study the   former smokers who had quit less than 1 
year prior to program   initiation. While other studies have 
removed them as well, it could further our understanding 
of recent versus nonrecent quitters. The number of years 
that former smokers smoked was not compared against the 
number of years the current smokers have been smoking. 
However, there are some reversible effects of smoking on 
lipid metabolism post-smoking cessation which may also 
confound the analysis.22
Future studies will aim to identify whether smoking ces-
sation and weight management can be tackled   simultaneously. 
For example, Persky et al suggest that eating and smoking 
may have shared functional or topographic features as adher-
ence to smoking cessation and dietary plans declined over 
time and co-varied throughout their study.11 According to 
Wee et al, adults younger than 30 years are more likely to 
smoke if they are trying to lose weight. However, smokers 
of all ages who are trying to lose weight are more likely to 
want to stop smoking.23
Table  5  Comparing  males  and  females  across  continuous 
physiological variables at program initiation
  Sex Description
Male  
N = 697
Female  
N = 1885
Systolic BP  
(mmHg) (SD)*
135.6 (24.3)  
344
129.8 (15.4)  
942
Males . Females
Diastolic BP 
(mmHg) (SD)* 
84.5 (9.6)  
344
81.5 (8.5)  
942
Males . Females
Total chol  
(mmol/L) (SD)* 
5.2 (1.0)  
467
5.32 (1.0)  
1454
Females . Males
ApoB (g/L) (SD)  1.1 (0.3)  
286
1.1 (0.3)  
825
Hba-1c (SD)  0.06 (0.0091)  
192
0.06 (0.0060)  
496
T3 (pmol/L)  
(SD) 
4.2 (0.74)  
405
3.9 (0.74)  
948
Males . Females
LDL  
(mmol/L) (SD)*
3.2 (0.79)  
439
3.3 (0.84)  
1392
Females . Males
Known sex differences
WC  
(inches) (SD)* 
53.7 (6.9)  
62.6
44.7 (6.1)  
1721
Males . Females
HDL  
(mmol/L) (SD)* 
1.0 (0.2)  
461
1.3 (0.3)  
1439
Females . Males
TGs  
(mmol/L) (SD)* 
2.04 (1.1)  
462
1.70 (0.9)  
1445
Males . Females
Notes: Mean values are presented +/- standard deviation (SD). *Indicates a significant 
difference at P , 0.05. Waist circumference (WC) in inches, blood pressure (BP) 
measured in mmHg, high-density lipoprotein (HDL) (mmol/L), triglycerides (TGs) 
(mmol/L), low-density lipoprotein (LDL) (mmol/L), apo-lipoprotein-B (Apo-B) (g/L), 
Hemoglobin-alc (Hba1c), triiodothyronine (T3) (pmol/L), total cholesterol (total 
chol) (mmol/L). The description column explains which groups had a higher value 
(.) for the particular variable studied. BP data is reported for patients who are not 
on medications which alter it. Lipid data is reported for patients who are not on lipid 
lowering agents. Glucose, Insulin and Hba1c data is reported for patients not being 
treated for T2DM. T3 data is represented for patients not on thyroid-hormone   
supplementation. All values in italics represent the number of patients for which a 
result was available.
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There are certainly clear clinical implications of this study. 
Physicians considering weight management for their patients 
should review the individual’s experience with smoking, their 
sex, age, etc. Knowledge of previous health scares, weight gain 
due to smoking cessation attempts, increased cardiovascular 
risk due to smoking and obesity are all important factors 
that a physician should consider when referring to weight 
management programs. Given that the obese former smokers 
suffer from more chronic diseases than never smokers, even 
with a mean cessation period of 10+ years, there is a danger 
in researchers and physicians combining never smokers with 
former smokers under the common label of “nonsmokers” in 
treatment decisions, or study design. A “nonsmokers” category 
which was created in Wilson et al9 would neglect the significant 
differences we have identified between former smokers and 
never smokers. The results of this study call for a longitudinal 
study comparing male smokers, male former smokers, male 
never smokers, female smokers, female former smokers and 
female never smokers on the 1-year-long weight management 
clinic program to see if the baseline differences identified here 
predict differences in program outcomes. If outcome differ-
ences do exist, there could be a strong argument for tailoring 
weight management programs to these unique groups.
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